Please login to the form below

Not currently logged in
Email:
Password:

eribulin

This page shows the latest eribulin news and features for those working in and with pharma, biotech and healthcare.

AZ and Merck & Co get FDA breast cancer nod for Lynparza

AZ and Merck & Co get FDA breast cancer nod for Lynparza

In the OLYMPIAD trial, Lynparza achieved a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) compared to standard chemotherapy (with capecitabine, vinorelbine or eribulin).

Latest news

  • NICE set to reject wider use of Eisai’s Halaven NICE set to reject wider use of Eisai’s Halaven

    Eisai’s Halaven (eribulin) should not be funded by the NHS for earlier use in breast cancer patients, according to draft guidance from NICE. ... According to the appraisal committee “it’s not clear whether the increase in overall survival is

  • AZ's Lynparza shows PARP inhibitor potential in breast cancer AZ's Lynparza shows PARP inhibitor potential in breast cancer

    Lynparza (olaparib) significantly improved progression-free survival (PFS) in women with HER2-negative metastatic breast cancer with a germline BRCA mutation, when compared with standard therapy with capecitabine, vinorelbine or eribulin

  • AZ moves closer to Lynparza filing in breast cancer AZ moves closer to Lynparza filing in breast cancer

    Compared to standard chemotherapy with capecitabine, vinorelbine or eribulin, Lynparza achieved a "statistically-significant and clinically-meaningful" improvement in progression-free survival (PFS) in the OLYMPIAD trial, said the company, although

  • NICE backs Eisai's Halaven for breast cancer NICE backs Eisai's Halaven for breast cancer

    The UK health technology assessment agency has approved Halaven (eribulin) for routine treatment of patients with locally advanced or metastatic breast cancer that has spread after two prior chemotherapy regimens. ... metastatic breast cancer in England

  • Lilly closes on first approval for sarcoma drug Lartruvo Lilly closes on first approval for sarcoma drug Lartruvo

    If approved, the drug will join other new therapies for STS, including Johnson &Johnson's chemotherapy agent Yondelis (trabectedin) and Eisai's Halaven (eribulin mesylate), both of which have been approved

More from news
Approximately 4 fully matching, plus 34 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...

Infographics